Search Results
Your search for The Editors,The Editors matches 99 pages
Showing 51 - 99New Leadership Elected to American Society of Hematology
The American Society of Hematology (ASH) recently announced the election of four new members to its Executive Committee for terms beginning after the 2016 ASH Annual Meeting, December 3–6, in San Diego. Roy L. Silverstein, MD, will serve a 1-year term as Vice President followed by successive...
ASCO Introduces Two New Journals: JCO Precision Oncology and JCO Clinical Cancer Informatics
ASCO is excited to launch two new online-only journals, JCO Precision Oncology (JCO PO) and JCO Clinical Cancer Informatics (JCO CCI). Both journals will be exploring the latest topics in oncology and filling a void for the oncology community. Manuscripts will go through the traditional peer-review ...
Chinese Journal of Cancer Extends Deadline for Submission of Most Important Questions in Cancer Research and Clinical Oncology
The Chinese Journal of Cancer (CJC) is soliciting the 150 most important questions in cancer research and clinical oncology from cancer researchers around the world. The editors of CJC believe this will help provide important insights and guidance in future efforts to advance cancer research...
Chinese Journal of Cancer Collecting 150 Most Important Questions in Cancer Research and Clinical Oncology
The Chinese Journal of Cancer (CJC) is soliciting the 150 most important questions in cancer research and clinical oncology from cancer researchers around the world. The editors of CJC believe this will help provide important insights and guidance in future efforts to advance cancer research...
Colleagues Tip Their Hats to Allen S. Lichter, MD, FASCO
After serving as ASCO’s CEO for 10 years, Allen S. Lichter, MD, FASCO, is stepping down. Dr. Lichter, who has been an ASCO member since 1980, has served the Society in numerous capacities. Along with his distinguished career at ASCO, Dr. Lichter is a nationally recognized radiation oncologist,...
Waun Ki Hong, MD, Receives 10th AACR Margaret Foti Award for Leadership and Extraordinary Achievements in Cancer Research
The American Association for Cancer Research (AACR) honored Waun Ki Hong, MD, with the 10th annual Margaret Foti Award for Leadership and Extraordinary Achievements in Cancer Research at the 2016 AACR Annual Meeting, held in New Orleans, April 16–20. The Margaret Foti Award for Leadership and...
Global Cancer: The Current Reality and the Future Need for Action
The estimated number of cancer cases worldwide in 2008 was 12.7 million, with 7.6 million deaths. By 2030, it is estimated that there will be 22 million newly diagnosed cancer cases and 12 million deaths, shocking to contemplate in dollars and human suffering. Although this impending disaster has...
Misconstrued Review
I’ve been a member of ASCO for longer than I can remember. I read most breast cancer–related articles in The ASCO Post and find them helpful, particularly the reports of as-yet-unpublished papers from meetings. So, it is with great disappointment that, in the November 10, 2015, issue, I read a...
Evolution
Ten years ago, ASCO created the Journal of Oncology Practice to address a gap in the literature; there were no peer-reviewed journals dedicated to the practical issues of delivering quality oncology care. The original research and editorials published in JOP focus on care delivery topics such as...
Do We Need the USPSTF?
Like most of the folks reading this commentary, I’m a taxpayer. Although I sometimes become impatient with the strategic games on Capitol Hill, I basically appreciate that government helps many things to work, and some of them even work well. However, there are aspects of government function that...
Reflections from The ASCO Post
The editors gratefully acknowledge all contributors to The ASCO Post and thank the columnists who contributed to Volume 2, January–December 2011: Al B. Benson III, MD, FACP Richard Boxer, MD, FACS Carlton G. Brown, RN, PhD, AOCN Barrie R. Cassileth, PhD E. David Crawford, MD Emil J. Freireich, MD, ...
Clinical Cancer Advances 2011: ASCO’s Report on Progress Against Cancer
This year marks the 40th anniversary ofthe National Cancer Act and places a more prominent focus on how much progress against cancer has been made over the past 4 decades. In the past year alone, significant advances have been made in cancer prevention and screening, hard-to-treat cancers, and...
JCO Presents New Training Seminar for Authors
Journal of Clinical Oncology (JCO) recently launched a training seminar for potential authors, entitled, “Publishing Your Research: A Seminar From the Editors of JCO.” The first seminar was held in January prior to the 2012 Gastrointestinal Cancers Symposium in San Francisco. Daniel G. Haller, MD,...
At More than a Century Old, American Association for Cancer Research Continues to Evolve
Margaret Foti, PhD, MD (hc), has been Chief Executive Officer of the American Association for Cancer Research (AACR) since 1982, and has been instrumental in launching some of the most seminal efforts of the cancer research organization. Over the past 4 years, she has helped spearhead the AACR’s...
Prostate Cancer Management: A Day Late and A Dollar Short?
In the May 15 issue, The ASCO Post reported on the relative cost-effectiveness of approaches to treating localized prostate cancer (“Advances in Prostate Cancer Accompanied by Ongoing Debates,” page 1). The article analyzed an important scientific paper presented at both urology and radiation...
Refining Current Treatments and Looking Ahead in HER2-positive Breast Cancer
In a study presented at the ASCO Plenary Session, trastuzumab emtansine (T-DM1), the antibody-drug conjugate linking trastuzumab (Herceptin) to a cytotoxic agent, improved progression-free survival by 3.2 months, representing a 35% reduction in risk of progression in the phase III EMILIA trial.1...
CancerProgress.Net Adds New Resources to Highlight Progress in Clinical Cancer Research
ASCO’s CancerProgress.Net (www.CancerProgress.Net), a dynamic website demonstrating four decades of progress against cancer, has added new resources that will enable site users to learn more about progress in cancer treatment, prevention, screening, and diagnosis. Interactive Cancer Timelines...
Clinical Cancer Advances 2012: ASCO’s Annual Report on Progress Against Cancer
Clinical research is continuously delivering new treatments that lengthen and improve the lives of patients with cancer. The abundance of advances reported in the past year illustrates our steady progress in cancer treatment and care. Clinical Cancer Advances 2012: ASCO’s Annual Report on Progress...
ASCO's CancerProgress.Net: Where We've Come From, Where We Are, and Where We're Going
The British science historian James Burke once wrote, “If you don’t know where you’ve come from, you don’t know where you are.” To tell the story of where we are in the treatment of people with cancer and how we got there, ASCO launched an ambitious history project in 2011 with a new website,...
ASCO University® Appoints First Editor-in-Chief
ASCO has appointed Daniel G. Haller, MD, as the first Editor-in-Chief of ASCO University®, an eLearning center designed to serve as the educational home for physicians, nurses, advanced practice providers, and patient educators at every stage of their careers. As head of the editorial board, Dr....
Clinical Cancer Advances 2013: ASCO's Annual Report on Progress Against Cancer
The Society has recently published Clinical Cancer Advances 2013: ASCO’s Annual Report on Progress Against Cancer, a comprehensive review of progress in clinical cancer research that has come to fruition in 2013. The report highlights advances across the entire continuum of cancer care, from...
NCI-Led Scientists Develop Criteria for 'Omics' Tests Used in Clinical Investigations
High-throughput “omics” technologies that generate molecular profiles on tumor specimens are increasingly being incorporated into clinical trials, but some of these assays have not been well validated, leading many in the research community to question their fitness for use in patient-care...
Science Magazine Names Cancer Immunotherapy as Scientific Breakthrough of the Year
While acknowledging that the full potential of cancer immunotherapy remains unclear, the editors of the journal Science said that the approach of using the immune system to attack tumors marks a turning point in the treatment of cancer.1 The successes of cancer immunotherapy in clinical trials in...
Major Cancer Advances in 2013 Highlight Importance of Federal Funding
About one-third of the most important clinical advances in cancer last year were made possible at least in part through federal funding, according to ASCO’s annual report on progress in cancer, published in the Journal of Clinical Oncology.1 Significant Declines in Funding The report, “Clinical...
Charting the Successes: CancerProgress.Net Chronicles More Than 50 Years of ASCO and Progress Against Cancer
On this historic year, as ASCO proudly commemorates its 50th anniversary and decades of evolutionary change and growth, it also celebrates the significant progress that has been made against cancer throughout history. ASCO’s anniversary website, CancerProgress.Net, chronicles these achievements and ...
Charting the Successes: CancerProgress.Net Chronicles More Than 50 Years of ASCO and Progress Against Cancer
On this historic year, as ASCO proudly commemorates its 50th anniversary and decades of evolutionary change and growth, it also celebrates the significant progress that has been made against cancer throughout history. ASCO’s anniversary website, CancerProgress.Net, chronicles these achievements and ...
Ceritinib Highly Active in Patients With ALK-Rearranged Advanced NSCLC
Non-small cell lung cancer (NSCLC) harboring ALK rearrangement is sensitive to the ALK inhibitor crizotinib (Xalkori), but resistance ultimately occurs. In a phase I study reported in The New England Journal of Medicine, Alice T. Shaw, MD, PhD, of Dana-Farber/Harvard Cancer Center, Boston, and...
Videos Tell Stories of 50 Years of Progress Against Cancer
Nearly 3 years ago, ASCO launched CancerProgress.Net to mark the 40th anniversary of the signing of the U.S. National Cancer Act, which led to major new investments in cancer research and significant increases in cancer survival. The site provides a dynamic and interactive history of progress...
Discontinuing Statins Near the End of Life Is Safe, Can Reduce Symptom Burden, and Is Generally Acceptable to Patients
Discontinuing statins for patients near the end of life is safe, saves money, spares patients from swallowing yet another pill and from the symptoms associated with statins, and is generally welcomed by patients. That last bit might come as a surprise to some physicians who worry that discontinuing ...
ASCO Convenes Think Tank to Tackle Disparities in Cancer Care
Despite advances in cancer screening and in more effective therapies to treat the disease, which have led to improved outcomes and increased survival rates for millions of people with cancer, not every American is reaping the benefits of these advances. Disparities in health-care access, quality of ...
A Conversation With Lidia Schapira, MD, the New JCO Art of Oncology Editor
The popular Art of Oncology (AOO) section of the Journal of Clinical Oncology (JCO) brings a human perspective to the art and science of practicing oncology. Lidia Schapira, MD, FASCO, Assistant Professor at Harvard Medical School and Massachusetts General Hospital, became the Art of Oncology...
Integrative Oncology: Mind, Body, and More
Bookmark Title: Integrative Oncology (Second Edition)Editors: Donald I. Abrams, MD, and Andrew T. Weil, MDPublisher: Oxford University PressPublication date: September 3, 2014Price: $65.00; Paperback, 848 pages In 1990, David Eisenberg, MD, from the Harvard School of Public Health, conducted a...
ASCO Seeks Editor for New Global Oncology Journal
The American Society of Clinical Oncology (ASCO) is seeking candidates for the position of founding Editor-in-Chief for a new online-only, open-access journal focusing on cancer care, research, and care delivery issues unique to limited health-care resource countries and settings. The new journal...
Striving for Quality, Not Quantity, of Life
Advances in science and medicine have led to humans living longer than at any other time in history. According to a new report1 on mortality from the Centers for Disease Control and Prevention’s National Center for Health Statistics, life expectancy in the United States is at an all-time high of...
Charting the Successes: CancerProgress.Net Chronicles More Than 50 Years of ASCO and Progress Against Cancer
On this historic year, as ASCO proudly commemorates its 50th anniversary and decades of evolutionary change and growth, it also celebrates the significant progress that has been made against cancer throughout history. ASCO’s anniversary website, CancerProgress.Net, chronicles these achievements and ...
ASCO Names Advance of the Year, Reviews Top Research Trends
In just a year’s time, four new therapies have been approved for patients with chronic lymphocytic leukemia (CLL), treatments that are highly effective and far easier for patients to tolerate. These therapies are a major step forward, bringing renewed hope to nearly 120,000 people living with CLL...
Two Case Reports on the Evaluation of Myeloid Neoplasm
The ASCO Post is pleased to introduce “Hematology Expert Review,” a new feature including a case report detailing a particular hematologic condition followed by questions. Answers to each question appear with expert commentary. In this first installment, we present two cases of older men with...
Prognostic Models and Front-Line Treatment Options for Chronic-Phase Chronic Myelogenous Leukemia
The ASCO Post is pleased to present “Hematology Expert Review,” an occasional feature that includes a case report detailing a particular hematologic condition followed by questions. Answers to each question, along with expert commentary, can be found in the sidebar. In this installment, we present...
PARP Inhibitors Have ‘Clear Benefit’ for Patients With Ovarian Cancer and BRCA Mutations, but When and at What Cost?
PARP inhibitors offer a promising alternative for targeted therapy in ovarian cancer” and have “clear benefit in BRCA-mutation carriers,” but questions remain about when is the best time to use them and the cost-effectiveness of maintenance therapy, Elizabeth M. Swisher, MD, of the University of...
Pioneer in Combination Chemotherapy, Vincent T. DeVita, Jr, MD, Changed the Face of Modern Oncology
As a young boy growing up in the Bronx, Vincent T. DeVita, Jr, MD, admired the local iceman, a thick-muscled guy known as Nunzi, who used to carry a big block of ice on his shoulder with a set of tongs, and effortlessly slide it into the DeVitas’ icebox. “A friend once asked me what I wanted to be...
Microangiopathic Hemolytic Anemia and Thrombocytopenia
The ASCO Post is pleased to present Hematology Expert Review, an occasional feature that includes a case report detailing a particular hematologic condition followed by questions. Answers to each question with expert commentary can be found in the sidebar. In this installment, we present the case...
Microangiopathic Hemolytic Anemia and Thrombocytopenia: Answers From Hematology Expert Review Questions
Question 1: What is the best first step in management of this patient? Correct Answer: C. Start plasma exchange. Expert Perspective Although distinguishing among thrombotic thrombocytopenic purpura, typical hemolytic uremic syndrome, and atypical hemolytic uremic syndrome (see Table 1 in the...
Strengthening the Doctor-Patient Relationship: An Interview With Lidia Schapira, MD, FASCO
Earlier this summer, Lidia Schapira, MD, FASCO, a medical oncologist at Massachusetts General Hospital Cancer Center and Associate Professor of Medicine at Harvard Medical School, was named Editor-in-Chief of Cancer.Net, ASCO’s patient information website. Prior to taking on this role, Dr....
Journal of Clinical Oncology Special Series Issues Provide Updates on Important Topics in Oncology Practice
Journal of Clinical Oncology (JCO) annually publishes several Special Series of reviews—disease-specific issues dedicated to providing readers with concise, authoritative updates on important topics in oncology practice. Each issue of the Special Series explores one specific area of cancer care...
Questions: Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System
Hematology Expert Review is an occasional feature that includes a case report followed by questions,answers, and expert commentary. In this issue of The ASCO Post, Drs. Abutalib and Lukas present part 1 of a case report on primary diffuse large B-cell lymphoma. Part 2 will be published in an...
Questions: Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System
The ASCO Post is pleased to present Hematology Expert Review, an occasional feature that includes a case report detailing a particular hematologic condition followed by questions. Answers to each question appear here with expert commentary. In the October 25 issue of The ASCO Post, part 1 of a...
Q: Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System
The ASCO Post is pleased to present Hematology Expert Review, an occasional feature that includes a case report detailing a particular hematologic condition followed by questions. Answers to each question appear on page 84 with expert commentary. In the November 10 issue of The ASCO Post, part 2 of ...
Genetic Test Predicts Colon Tumor Sensitivity to Radiation Therapy
Recent advances in the understanding of cancer have led to the development of more personalized therapies. Moffitt Cancer Center researchers have contributed to these advances by developing the first test that analyzes the sensitivity of tumors to radiation therapy. Their findings were published by ...
Science Magazine Names Cancer Immunotherapy as Scientific Breakthrough of the Year
While acknowledging that the full potential of cancer immunotherapy remains unclear, the editors of the journal Science said that the approach of using the immune system to attack tumors marks a turning point in the treatment of cancer. The successes of cancer immunotherapy in clinical trials in...
